PETER MANU, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Amikacin, a semisynthetic derivative of kanamycin A, was approved for unrestricted clinical use in 1976 and is considered the antibiotic of choice for use against infections with gentamicin-resistant, gram-negative bacilli (1, 2). In a recent issue, Betts and colleagues (3) have reported data on the use of amikacin as the primary empiric aminoglycoside in a large university hospital. The authors have concluded that "because it is not possible to identify patients infected with gentamicin-resistant organisms until 48 hours after therapy is initiated, it is rational to use an antibiotic agent that is likely to be effective against
MANU P. Empiric Use of Aminoglycosides in Hospitals. Ann Intern Med. 1984;100:919–920. doi: 10.7326/0003-4819-100-6-919_2
Download citation file:
Published: Ann Intern Med. 1984;100(6):919-920.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use